Table 1.
CTL | sMCI | cMCI | AD | Total | |
---|---|---|---|---|---|
Number of participants | 214 | 200 | 55 | 197 | 666 |
Age | |||||
Mean sd | |||||
Sex | |||||
Male | 103 | 99 | 20 | 101 | 323 |
Female | 111 | 101 | 35 | 96 | 343 |
MMSE score | |||||
Mean sd | |||||
Metabolic UHPLC-MS data obtained | 172 | 167 | 45 | 177 | 561 |
Metabolic NMR data obtained | 174 | 173 | 46 | 182 | 575 |
Metabolic data obtained (UHPLC-MS and NMR) | 132 | 140 | 36 | 162 | 470 |
Genetic and metabolic UHPLC-MS data available | 119 | 80 | 24 | 122 | 345 |
Genetic and metabolic NMR data available | 120 | 83 | 23 | 126 | 352 |
APOE genotype available | 154 | 155 | 44 | 174 | 527 |
APOE genotype | |||||
E3E3 | 84 | 84 | 13 | 70 | 251 |
E3E4 | 37 | 50 | 24 | 66 | 177 |
E2E3 | 22 | 10 | 4 | 9 | 45 |
E4E4 | 7 | 7 | 3 | 27 | 43 |
E2E4 | 3 | 4 | 0 | 2 | 9 |
E2E2 | 1 | 1 | 0 | 0 | 2 |
CTL normal cognition (control) participants, sMCI stable mild cognitive impairment, cMCI mild cognitive impairment converting to dementia, AD participants with Alzheimer’s disease, MMSE Mini-Mental State Examination.